BACKGROUND: Engagement of all known Toll-like receptors (TLRs) causes the production of inflammatory cytokines, including TNF-alpha, whereas in humans, engagement of TLRs 3, 7, 8, and 9 also induces type I IFNs. IRAK-4 is a critical effector in signaling by TLRs and the IL-1 receptor, which share homology in their intracellular domain and recruit IRAK-4 via the adaptor myeloid differentiation factor 88 (MyD88). Patients with IRAK-4 deficiency are susceptible to invasive bacterial infections but have so far not been reported to be susceptible to viral infection. Blood cells from these patients are impaired in their ability to make TNF-alpha in response to activation by TLRs. A recent report has described concomitant impairment of type I IFN production after activation of TLRs 7, 8, and 9, but not TLR3. OBJECTIVES: We sought to evaluate the role of IRAK-4 in TLR-induced production of the type I IFN, IFN-alpha, in humans. METHODS: We examined TLR-induced production of TNF-alpha and IFN-alpha in PBMCs from an IRAK-4-deficient patient, his heterozygous carrier parents, and normal controls. RESULTS: TNF-alpha production in response to TLR agonists was severely impaired in the patient. IFN-alpha production induced by TLR7, TLR8, and TLR9, as well as TLR3 agonists, was low or absent. CONCLUSIONS: IRAK-4 plays an important role in the production of type I IFN, as well as TNF-alpha, induced by all TLRs, including TLR3. CLINICAL IMPLICATIONS: IRAK-4 may play a broader role in human innate antiviral immunity than previously appreciated.
BACKGROUND: Engagement of all known Toll-like receptors (TLRs) causes the production of inflammatory cytokines, including TNF-alpha, whereas in humans, engagement of TLRs 3, 7, 8, and 9 also induces type I IFNs. IRAK-4 is a critical effector in signaling by TLRs and the IL-1 receptor, which share homology in their intracellular domain and recruit IRAK-4 via the adaptor myeloid differentiation factor 88 (MyD88). Patients with IRAK-4 deficiency are susceptible to invasive bacterial infections but have so far not been reported to be susceptible to viral infection. Blood cells from these patients are impaired in their ability to make TNF-alpha in response to activation by TLRs. A recent report has described concomitant impairment of type I IFN production after activation of TLRs 7, 8, and 9, but not TLR3. OBJECTIVES: We sought to evaluate the role of IRAK-4 in TLR-induced production of the type I IFN, IFN-alpha, in humans. METHODS: We examined TLR-induced production of TNF-alpha and IFN-alpha in PBMCs from an IRAK-4-deficient patient, his heterozygous carrier parents, and normal controls. RESULTS:TNF-alpha production in response to TLR agonists was severely impaired in the patient. IFN-alpha production induced by TLR7, TLR8, and TLR9, as well as TLR3 agonists, was low or absent. CONCLUSIONS:IRAK-4 plays an important role in the production of type I IFN, as well as TNF-alpha, induced by all TLRs, including TLR3. CLINICAL IMPLICATIONS: IRAK-4 may play a broader role in human innate antiviral immunity than previously appreciated.
Authors: Douglas R McDonald; Frederick Goldman; Oscar D Gomez-Duarte; Andrew C Issekutz; Dinakantha S Kumararatne; Rainer Doffinger; Raif S Geha Journal: J Allergy Clin Immunol Date: 2010-08 Impact factor: 10.793
Authors: Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek Journal: Clin Microbiol Rev Date: 2011-07 Impact factor: 26.132
Authors: Jana L Mooster; Caterina Cancrini; Alessandra Simonetti; Paolo Rossi; Gigliola Di Matteo; Maria Luisa Romiti; Silvia Di Cesare; Luigi Notarangelo; Raif S Geha; Douglas R McDonald Journal: J Allergy Clin Immunol Date: 2010-06-12 Impact factor: 10.793
Authors: Cheng-Lung Ku; Horst von Bernuth; Capucine Picard; Shen-Ying Zhang; Huey-Hsuan Chang; Kun Yang; Maya Chrabieh; Andrew C Issekutz; Coleen K Cunningham; John Gallin; Steven M Holland; Chaim Roifman; Stephan Ehl; Joanne Smart; Mimi Tang; Franck J Barrat; Ofer Levy; Douglas McDonald; Noorbibi K Day-Good; Richard Miller; Hidetoshi Takada; Toshiro Hara; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; David Speert; Damien Sanlaville; Xiaoxia Li; Frédéric Geissmann; Eric Vivier; László Maródi; Ben-Zion Garty; Helen Chapel; Carlos Rodriguez-Gallego; Xavier Bossuyt; Laurent Abel; Anne Puel; Jean-Laurent Casanova Journal: J Exp Med Date: 2007-09-24 Impact factor: 14.307